Evaluation of the Prognostic Value of PET/MRI in Cardiac Sarcoidosis
Recruiting
N/A
Interventional Study
Cardiac Sarcoidosis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 180 (estimated)
- Sponsor
- Assistance Publique - Hôpitaux de Paris · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Cardiac damage is the second leading cause of death in patients with sarcoidosis, after lung damage. Today's challenge is to diagnose the disease as effectively as possible, and to develop tools for better risk stratification, especially for sudden death, in order to better target therapies and implantable devices, such as corticoids and immunosuppressant.
The hypothesis is that combined PET (Pos…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age ≥ 18 years
* Sarcoidosis defined according to ATS/ERS/WASOG criteria
* Suspicion of cardiac involvement in sarcoidosis:
* Clinical manifestations (syncope, lipothymia, persistent palpitations, signs of heart failure) and/or
* Cardiac rhythm or conduction disorder (Mob…
Contacts